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Objective: The objective of this study was to apply the newly standardized definition for
sarcopenia from the Foundation for the National Institutes of Health (FNIH) and the current
definition for obesity to 1) determine the prevalence of sarcopenic obesity (SO) in obese elderly
women; 2) compare the muscle strength, lean body mass, and markers of inflammation between
obese elderly women with SO and nonsarcopenic obesity (NSO), and 3) elucidate the relationship between appendicular lean mass adjusted for body mass index (aLM/BMI) with muscle
strength, lean body mass, and obesity indices.
Methods: A total of 64 elderly obese women (age: 68.35±6.04 years) underwent body composition analysis by dual-energy X-ray absorptiometry. Participants were classified into two groups
according to the definition of SO and NSO. Blood samples were collected for total cholesterol,
triglycerides, high-density lipoprotein, low-density lipoprotein, uric acid, urea, interleukin-6
(IL-6), glucose, and creatine kinase (CK) measurements.
Results: The SO group presented a significantly greater BMI, fat (%), glucose, a marginal
trend toward significance for uric acid, and IL-6 compared to the NSO group. In addition, the
SO group displayed lower values for muscle strength and lean body mass. From a correlation
standpoint, a higher aLM/BMI was positively associated with lean body mass and muscle
strength and negatively associated with a lower BMI and percentage body fat.
Conclusion: The definition criteria from FNIH and obesity permit the ability to illustrate the
prevalence and identify SO in elderly women with low muscle mass, low muscle strength, and
impaired markers of inflammation.
Keywords: aging, fat mass, muscles, obesity, sarcopenia, sarcopenic obese

Introduction
During aging, a decline in muscle mass coupled with an increase in fat mass has important consequences for older adults.1 Four body composition phenotype characteristics
exist in older adults: normal, sarcopenic, obese, and a combination of sarcopenic and
obese.2 Although the definition of sarcopenic obesity (SO) combines those of sarcopenia
and obesity, few diagnostic methods have been proposed in recent years.2–4
Obesity can be diagnosed by total fat mass, percentage body fat, body mass index
(BMI), visceral fat area, and waist circumference, while sarcopenia can be diagnosed
by appendicular lean mass adjusted for height squared (aLM/height2 or BMI [aLM/
BMI]).6 The aLM/height2 method has been widely used in many studies, while the
aLM/BMI method represents a new clinically relevant criteria for weakness and low
muscle mass based on a large, diverse, and well characterized set of populations of
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community-dwelling elderly persons that permit generalizability of findings.1,5–9
The combination of sarcopenia and obesity has a detrimental impact on physical functional status in obese elderly
women, which in turn exacerbates disability.2,10 SO is also
associated with systemic inflammation (eg, higher C-reactive
protein, fibrinogen, interleukin-6 [IL-6]), lower handgrip
strength, lower lean body mass, higher mortality risk, lower
muscle quality caused by fat infiltration, impaired quality of
life, higher cardiovascular disease risk, and more physical
disabilities when compared with subjects without SO.3,8,11–16
Considering that SO research is in its infancy and different mathematical thresholds can over- and under-diagnose
this clinical condition, our goal was to 1) apply the newly
standardized definition for SO used in previous studies and
proposed by the Foundation for the National Institutes of
Health (FNIH) and illustrate the prevalence of SO in obese
elderly women; 2) observe the degree of impairment of
muscle strength, lean body mass, and markers of inflammation in those fulfilling such criteria; and 3) elucidate the
association between aLM/BMI with obesity indices and
strength parameters.6,8,9,11,17
We hypothesized that obese elderly women with SO will
have higher pro-inflammatory markers when compared to
NSO elderly women. Furthermore, we hypothesized that
a higher aLM/BMI will be positively associated with lean
body mass and muscle strength and negatively associated
with obesity indices.

Materials and methods
Ninety elderly women from a local community were
recruited through posters and lectures about the study at
the Federal District, Brazil. To be eligible, women needed
to be aged ≥60 years with a body fat percentage ≥38% as
assessed by dual-energy X-ray absorptiometry (DXA).11,17
Exclusion criteria included history of heart failure, valvular
or congenital disease, pacemaker implantation, or osteoarticular disorders. A total of 90 older women were assessed
for eligibility and completed a self-report questionnaire that
accounted for cardiovascular disease, hypertension, diabetes,
osteoporosis, or musculoskeletal conditions that may have
precluded participants from safely completing physical
function tests assessed in this study. Elderly women were
classified as hypertensive and with type 2 diabetes mellitus by the diagnostic criteria used in previous studies.18–20
From the initial applicants, 26 were excluded (did not meet
inclusion criteria) and thus a total of 64 women who met the
inclusion criteria were selected to participate. The present
study was approved by the Institutional Research Ethic Com444
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mittee of Catholic University of Brasília (UCB) (protocol
#035/2011). The study design and employed procedures
were in accordance with ethical standards and the Declaration of Helsinki. Each participant was fully informed about
the risks associated with study participation and gave their
written informed consent.

Muscle strength evaluation
Muscle strength was evaluated by the ten-repetition maximum (10 RM) test according to the protocol used in previous
research from our laboratory.21,22 The test-retest reproducibility for the leg extension 10 RM was R=0.99. In addition,
the relative muscle strength was calculated by dividing the 10
RM test value by body mass.23 In addition, the leg extension
exercise was chosen because lower limb strength has a strong
correlation with elderly survival time and dependency.24

Blood samples and biochemical
parameters
Lipid profile glycerol phosphate dehydrogenase/p-chlorophenol in presence of peroxidase, urea (Ureasi-glutamate
dehydrogenase), and uric acid (uricase/peroxidase method)
were measured by the enzymatic colorimetric method using
Autohumalyzer equipment (Human GMBH, Wiesbaden,
Germany). High-density lipoprotein cholesterol was determined by ionic exchange followed by colorimetric reaction
with the Linco Research Inc. kit (St Louis, MO, USA), and
blood glucose was measured by the hexokinase enzymatic
assay. IL-6 concentration was measured by Quantikine highsensitivity commercial enzyme-linked immunosorbent assay
kit (R&D Systems, Minneapolis, MN, USA). The intraassay
coefficient of variation of the kit was 1.5%–5.6% for IL-6.
The inter-assay coefficient of variation was 4.3%–6.4% for
IL-6. Creatine kinase (CK) concentration was determined by
using a commercially available Reflotron CK assay using the
Reflotron system (Boehringer Mannheim GmbH, Mannheim,
Germany). The measures for CK and IL-6 were performed
in triplicate and then averaged.

Body composition
Body composition procedures have been described in detail
elsewhere, and percent body fat and appendicular skeletal
muscle mass were determined via DXA (General Electric-GE
model 8548 BX1L, year 2005, Lunar DPX type, Software
Encore 2005; Rommelsdorf, Germany). The coefficient of
variation for the percent body fat estimated by DXA was
10.12% and 12.13% for the SO and nonsarcopenic obesity
(NSO) groups, respectively. All metal objects were removed
from the participants before the scan.25
International Journal of General Medicine 2018:11
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Sarcopenia and SO
Prevalence of sarcopenia was defined by the aLM adjusted
for BMI <0.512.6,8 Obesity was considered as a body fat
percentage ≥38%. SO was determined if elderly women
fulfilled the criteria for both sarcopenia and obesity using
these definitions.4–6,11,17

Statistical analysis
All analyses were conducted with SPSS software version
18.0 (SPSS Inc., Chicago, IL, USA) and the normality
was verified by the Shapiro–Wilk test. For the parametric
and non-parametric data, an independent Student’s t-test
and Mann–Whitney U test were employed, respectively. In
addition, the Spearman’s rank correlation coefficient was
used to test the association of aLM/BMI with biochemical
parameters, muscle strength, and body composition. A chisquared test for proportions (Fisher’s exact test when cells
with expected values were <5 for essential hypertension and
type 2diabetes mellitus) was also employed. An alpha level
of P≤0.05 was considered significant. In addition, GraphPad
Prism 7.0 software was also used (GraphPad Software, Inc.,
La Jolla, CA, USA). An effect size d of 2.31, a power >80%,
alpha error probability of 0.05, allocation ratio of 1.06, and
two tails were considered. The post hoc power analysis was
used to calculate the sample size necessary to identify differences between two independent groups. Sixty-two elderly
(31 vs 31) women were necessary to identify a difference on
aLM adjusted for BMI. For the power calculation, the software G*Power 3.1.6 was used (Heinrich-Heine-University
Düsseldorf, Düsseldorf, Germany).

Results
The SO group presented a significantly lower absolute
muscle strength (35.60±7.88 kg [37.71–38.50 95% CI] vs
40.30±8.38 kg [37.32–43.27 95% CI]) and relative muscle
strength (0.51±0.12 kg/kg [0.47–0.56 95% CI] vs 0.60±0.12
kg/kg [0.56–0.65 95% CI]), arm lean body mass (3.76±0.55
kg [3.56–3.97 95% CI] vs 4.02±0.60 kg [3.80–4.23 95% CI]),
leg lean body mass (10.90±1.28 kg [10.43–11.37 95% CI] vs
11.76±1.22 kg [11.33–12.20 95% CI]), and aLM (14.67±1.58
kg [14.09–15.25 95% CI] vs 15.79±1.60 kg [15.22–16.36
95% CI]) compared to the NSO group (Figure 1).
Furthermore, the SO group presented a significantly
greater BMI, fat (%), glucose, and a marginal trend toward
significance for uric acid, and IL-6 (4.76±5.46 pg/ml
[2.76–6.80 95% CI] vs 2.58±3.00 pg/ml [1.51–3.64 95% CI])
compared to the NSO group (Table 1; Figure 1). In addition,
there was a significant positive correlation between aLM/
BMI with relative muscle strength, arm lean body mass, leg
International Journal of General Medicine 2018:11
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lean body mass, and aLM. However, there was also a significant negative correlation between aLM/BMI with body
fat percentage (Table 2). Furthermore, a marginal trend was
observed for a negative correlation with glucose.
There was no statistical difference between groups for
the presence of hypertension (X²(1) =0.21, P=0.80, Cramer’s V=0.05) and diabetes (X²(1) =0.00, P=1.00, Cramer’s
V=0.01).

Discussion
Our results highlight the prevalence of SO in a relatively
small sample of obese elderly women using the newly standardized FNIH definition of ALM combined with obesity
based on body composition. In addition, our results indicate
that elderly women with SO present lower levels of lean
body mass and muscle strength, higher glucose, and a trend
toward a statistical significance for a higher uric acid and IL-6
serum levels as compared with NSO elderly women. Other
important findings include a positive correlation between
aLM/BMI with lean body mass and muscle strength, and
a negative association with BMI and percentage body fat.
Inflammation associated with SO plays an important
role in insulin resistance, glucose tolerance, reduced lean
body mass, and lower muscle strength.3,16,26,27 An alternative
hypothesis for the higher glucose levels observed in the
SO group is that rather than low levels of lean body mass
being responsible for glucose intolerance, the condition may
instead be primarily a function of the higher accumulation
of visceral fat.28
This might be explained by the superior IL-6 serum levels
when compared with the NSO group. In addition, chronic
IL-6 elevations activate the transcription nuclear factor-kB
and JUN N-terminal kinase pathways associated with insulin
resistance,27,29 thus promoting a higher level of glucose in the
SO group compared with NSO group as verified in this study.
Furthermore, higher IL-6 serum levels are observed in
individuals with obesity and poor muscle strength.16 Consistent with this result, we found a trend for greater IL-6 serum
levels in the SO group. Moreover, the low muscle strength
and lean body mass observed in the SO group might be
explained by the activation of molecular pathways as FOXO,
Smad 2/3, p38MAPK promoted by IL-6 that causes protein
degradation by the ubiquitin ligases and thereby negatively
regulates muscle mass and strength in sarcopenic individuals.30 Although no standard for IL-6 serum levels has been
established for reference in clinical practice, older women
with high IL-6 serum levels (>3.10 pg/mL) have a higher risk
of developing physical disabilities (eg, associated with low
muscle strength) as observed in the present study for the SO
submit your manuscript | www.dovepress.com
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Figure 1 Comparisons between sarcopenic obesity and nonsarcopenic obesity presented by mean and SD.
Notes: Non-normal data (relative muscle strength, leg lean mass, appendicular lean mass, and interleukin-6), P≤0.05.
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Table 1 Participant characteristics presented by mean, SD, and 95% CI
Age (years)*
Body weight (kg)
BMI (kg/m²)*
Height (m)
Fat (%)*
Fat (kg)*
aLM/BMI*
Total cholesterol (mg/dL)
Triglycerides (mg/dL)*
HDL (mg/dL)
LDL (mg/dL)
Uric acid (mg/dL)
Urea (mg/dL)
CK (U/L)*
Glucose (mg/dL)*

SO (N=31)

NSO (N=33)

P-value

68.19±5.06 (66.33–70.05)
70.11±12.82 (65.41–74.82)
31.19±4.35 (29.60–32.79)
1.49±0.05 (1.47–1.51)
45.17±4.46 (43.54–46.81)
30.44±8.71 (27.24–33.63)
0.43±0.03 (0.46–0.48)
215±32.45 (203.48–227.71)
155.50±57.94 (133.86–177.13)
47.60±11.69 (43.23–51.96)
137.24±32.27 (125.18–149.29)
5.10±1.51 (4.53–5.67)
33.28±7.14 (30.61–35.95)
94.56±33.82 (81.93–107.19)
108.52±39.84 (93.64–123.40)

68.51±6.91 (66.06–70.96)
66.90±10.42 (63.20–70.59)
27.76±3.98 (26.34–29.17)
1.55±0.04 (1.53–1.56)
42.97±3.54 (41.71–44.22)
28.47±5.75 (26.43–30.51)
0.57±0.08 (0.54–0.60)
209.42± (196.72–222.12)
145.57±62.09 (123.55–167.59)
46.21±11.35 (42.18–50.24)
134.06±33.10 (134.06–122.32)
4.48±1.23 (4.05–4.92)
36.21±8.34 (33.25–39.17)
104.54±44.00 (88.94–120.14)
95.48±21.40 (87.89–103.07)

0.859
0.274
0.002
0.001
0.050
0.532
0.001
0.482
0.372
0.629
0.711
0.084
0.142
0.215
0.010

Note: *Non-normal data.
Abbreviations: aLM, appendicular lean mass, BMI, body mass index, HDL, high-density lipoprotein, LDL, low-density lipoprotein, CK, creatine kinase, SO, sarcopenic
obesity, NOS, nonsarcopenic obesity.

Table 2 Correlation coefficient between aLM/BMI and
biochemical parameters, muscle strength, and body composition
Correlation coefficient
IL-6 (pg/mL)
Glucose (mg/dL)
Uric Acid (mg/dL)
Absolute muscle strength (kg)
Relative muscle strength (kg)
Arms lean body mass (kg)
Legs lean body mass (kg)
aLM (kg)
BMI (kg/m²)
Fat (%)

R

P-value

–0.18
–0.22
–0.15
0.17
0.32
0.24
0.32
0.35
–0.53
–0.39

0.153
0.080
0.214
0.167
0.001
0.056
0.002
0.004
0.001
0.001

Note: P≤0.05, significant difference.
Abbreviations: IL-6, interleukin-6, aLM, appendicular lean mass, BMI, body mass
index.

group when compared with the NSO group (4.76 vs 2.58 pg/
mL for IL-6, respectively).22,26
On the basis of this finding, SO demonstrated a statistical trend for higher uric acid when compared to NSO group.
One possible explanation is that visceral adiposity demonstrates a higher urinary excretion (eg, overproduction-type
hyperuricemia).31 In addition, central obesity (aka visceral
adiposity) is associated with a proinflammatory condition
and insulin resistance.16,32 Central obesity to a greater extent
directly affects inflammation, functional impairment, and uric
acid serum levels.16,31,33 SO group in our study might have
a central obesity characteristic rather than regional obesity
when compared with NSO, although not directly verified

International Journal of General Medicine 2018:11

by DXA. Furthermore, uric acid might also induce insulin
resistance, which could partially explain the higher glucose
serum levels observed in the SO group.32
SO has been shown to be related to physical limitations,
impaired basic activities of daily living, and impaired instrumental activities of daily living.9 The low muscle strength
observed in our SO group may increase the likelihood for
these maladies and lead to premature mortality.12 Thus, maintaining a higher aLM/BMI is positively associated with lean
body mass and muscle strength while negatively associated
with a lower BMI and percent body fat. Furthermore, there
was a trend toward a negative association with glucose tolerance, which may have beneficial health implications.
Our exploratory analysis provides additional insight
into the relationship between SO, inflammation, low muscle
strength, glucose intolerance, and uric acid concentrations.
However, these important findings are highly dependent on the
specific definitions used for sarcopenia and obesity, which may
result in over- or under-diagnosis of this clinical condition.6,11,17
Accordingly, our findings would necessarily change when
a different method is employed.5,7 Although this represents an
important limitation, our results corroborate the relationship
between SO and functional disabilities and inflammation where
using the aLM/BMI method demonstrated stronger strengths of
associations and clinical applicability.8,9 Our findings are also
limited by the relatively small sample size that compromises
statistical power, how well the sample reflected the true underlying population of obese elderly women, and the cross-sectional
design employed precludes the determination of causality.
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In addition, we suggest the need of other strength measures to be comparable with other studies of sarcopenia and
the need for future research including more details regarding visceral fat such as waist–hip ratio or separation of fat
deposits using DXA or other imaging measures.

Conclusion
Our results suggest that SO in elderly women is associated
with higher IL-6 serum levels, lower muscle strength, lower
lean body mass, higher glucose, and higher uric acid levels.
Furthermore, the use of definition criteria from FNIH and
obesity might permit the identification of elderly women
with SO and allow researchers in clinical geriatric practice to
plan possible interventions to reduce the burden of disability
downstream.6,11,17
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